INMD (Update)

Inmode Ltd

Healthcare


Presented:03/22/2021
Price:$18.34
Cap:$1.40B
Current Price:$16.65
Cap:$1.41B

Presented

Date03/22/2021
Price$18.34
Market Cap$1.40B
Ent Value$1.75B
P/E Ratio17.98x
Book Value$3.36
Div Yield0%
Shares O/S76.38M
Ave Daily Vol3,053,356
Short Int3.76%

Current

Price$16.65
Market Cap$1.41B
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Please note, this is an update to Inmode Ltd (INMD) - Long, which was first presented on 08/17/2020. As well, please note, this stock split on 09/30/2021 at a ratio of 2/1. The presented data has been updated, however, the text of the note may refer to data based on the original presented price of $30.99.

Publicly traded companies mentioned herein: InMode Ltd (INMD)

Highlights

The presenter is long shares of Inmode Ltd (INMD), reiterating his bullish stance on the stock based on an earlier pitch in August 2020. INMD is a $3B company that develops, manufactures, and markets medical technology platforms focused on patients seeking aesthetic improvements (e.g., tightening up the waistline or face). INMD’s workstation products include, but are not limited to: BodyTite, Contoura, Votiva and Morpheus8.

Overall, the presenter believes that companies such as INMD have benefitted from COVID-related tailwinds. High-net-worth consumers in the US have higher than average savings due to reduced spending (fewer to no vacations, dining out less frequently, etc.). This dynamic has resulted in a boom in the aesthetics market. 

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.